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MCSF drives regulatory DC development in
stromal co-cultures supporting
hematopoiesis
Sawang Petvises1,2, Pravin Periasamy1,3 and Helen C. O’Neill1,4*
Abstract
Background: Splenic stroma overlaid with hematopoietic progenitors supports in vitro hematopoiesis with
production of dendritic-like cells. Co-cultures of murine lineage-depleted bone marrow over the 5G3 stromal
line produce two populations of cells, characterised as CD11b+CD11c+MHC-II− dendritic-like ‘L-DC’, and
CD11b+CD11c+MHC-II+ cells, resembling conventional dendritic cells (cDC). To date, the functional capacity of
these two subsets has not been clearly distinguished.
Results: Here we show both the L-DC and cDC-like subsets can be activated and induce proliferation of OT-I CD8+ T
cells, being strong inducers of IL-2 and IFN-γ production. Both subsets lack ability to induce proliferation of OT-II CD4+
T cells. The cDC-like population is shown here to resemble regulatory DC in that they induce FoxP3 expression and IL-
10 production in OT-II CD4+ T cells, in line with their function as regulatory DC. L-DC did not activate or induce the
proliferation of CD4+ T cells and did not induce FoxP3 expression in CD4+ T cells. L-DC can be distinguished from cDC-
like cells through their superior endocytic capacity and expression of 4-1BBL, F4/80 and Sirp-α. A comparison of gene
expression by the two subsets was consistent with L-DC having an activated or immunostimulatory DC phenotype,
while cDC-like cells reflect myeloid dendritic cells with inflammatory and suppressive properties, also consistent with
functional characteristics as regulatory DC. When a Transwell membrane was used to prevent hematopoietic cell
contact with stroma, only cDC-like cells and not L-DC were produced, and cell production was dependent on M-CSF
production by stroma.
Conclusion: Co-cultures of hematopoietic progenitors over splenic stroma produce two distinct subsets of
dendritic-like cells. These are here distinguished phenotypically and through gene expression differences.
While both resemble DC, there are functionally distinct. L-DC activate CD8+ but not CD4+ T cells, while the
cDC-like population induce regulatory T cells, so reflecting regulatory DC. The latter can be enriched through
Transwell co-cultures with cell production dependent on M-CSF.
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Background
Dendritic cells (DC) are potent antigen presenting cells
(APC) essential for activation of naïve T cells [1]. While DC
are clearly important in activation of T cell immunity, they
also play an important role in immune tolerance and
homeostasis through suppression of T cell activation and
function [2, 3]. While immune activating DC are typified by
the main splenic subsets of conventional (c) and plasmacy-
toid (p) DC, tolerising or regulatory DC (DCregs) are less
well defined, with heterogeneity already reported within the
field [4]. In general, DCregs are dendritic-like cells distinct
by their CD11bhiCD11clo phenotype with low expression of
both MHC-II and costimulatory molecules like CD40,
CD80 and CD86 [5]. The important involvement of DCregs
in controlling autoimmunity and allograft rejection can be
attributed to their specific ability to induce the production
of FoxP3-expressing regulatory T cells (Tregs) which sup-
press activation of antigen-specific T cells [4, 5]. The
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therapeutic importance of this DC subset has led to a num-
ber of studies on the production of DCregs in vitro with
a view to their use in cell therapy [4, 6].
The importance of the stromal microenvironment in
production of DCregs has been demonstrated for mul-
tiple tissues including spleen, liver, lung and even tu-
mours [7–11]. Several reports indicate production of
DCregs in vitro through co-culture of bone marrow
above splenic stromal cells [9, 11–13]. However, the stro-
mal cell contribution to DCreg production, and the path-
way to development are not well characterised. Previous
studies from this lab have shown that continuous long-
term spleen stromal cultures support production of dis-
tinct CD11bhiCD11clo dendritic-like cells lacking MHC-II
expression and reflecting immature myeloid dendritic
cells (DC) [14]. Most work has been directed at charac-
terisation of this novel dendritic-like cell called ‘L-DC’
which is produced continuously in these cultures [15,
16]. These findings also led to the hypothesis that
hematopoietic stem or progenitor cells were maintained
within cultures [17–19]. Stromal lines isolated from
spleens of mouse [20–22] have since been shown to sup-
port restricted myelopoiesis from overlaid bone marrow
progenitors with highly reproducible production of two
distinct dendritic-like subsets [22–25]. These two distinct
subsets are not developmentally linked and arise through
differentiation of distinct progenitors/precursors [23, 24].
The progenitor source of cells produced was identified
when highly purified hematopoietic stem cells and pro-
genitors were overlaid above stroma [16, 24, 26]. The
production of CD11b+CD11c+MHC-II−CD8α- ‘L-DC’ was
shown to be continuous and dependent on overlay of
early hematopoietic stem cells or multipotential progeni-
tors above the stroma [16]. A second subset of
CD11b+CD11c+MHC-IIloCD8α− DC resembling well
known conventional (c) DC was found to be transiently
produced and dependent on overlay of myeloid progeni-
tors present in mouse bone marrow [16]. L-DC activate
CD8+ T cells, but not CD4+ T cells [23, 24]. The
cDC-like population is produced transiently for only 2–
4 weeks, consistent with development from myeloid pre-
cursors which are not self-renewing. Because these
cDC-like cells have limited replicative capacity in stromal
co-cultures, their functional capacity has not been fully
established [24]. They are here investigated in terms of
their similarity with L-DC and with reported subsets of
DCregs produced in vitro.
Results
Production of dendritic-like cells in stromal co-cultures
Co-cultures of 5G3 stroma were established with Lin− bone
marrow from C57BL/6 J mice as an overlay to establish
hematopoiesis for production of dendritic-like cells. Growth
of hematopoietic cells was evident over time (Fig. 1).
Non-adherent cells were collected and analysed by antibody
staining and flow cytometry at 14, 21 and 28 days to detect
the two common dendritic-like subsets previously de-
scribed [23, 24]. Analysis involved gating PI− live large
(FSChi) cells on the basis of CD11b and CD11c expression
(Fig. 1B). The CD11b+CD11c+ subset of dendritic-like cells
was then further divided on the basis of MHC-II, CD8α
and B220 expression for delineation of
CD11b+CD11c+MHC-II−CD8α−B220− ‘L-DC’ and
CD11b+CD11c+MHC-II+CD8α−B220− ‘cDC-like cells’ as
described previously [23, 24]. The production of
CD11b+CD11c+ dendritic-like cells stably increased in
co-cultures over time, approaching 80% at 21 and 28 days
(Fig. 1C). A 40% subset of CD11b+CD11c− myeloid cells
was observed at 14 days, with a significant decrease in this
population to < 15% by 21 days. The CD11b−CD11c− pro-
genitor subset was maintained at < 10% over time. L-DC as
CD11b+CD11c+MHC-II− cells were the majority popula-
tion representing > 90% of CD11b+CD11c+ cells, with a
minor subset (< 8%) of cDC-like as
CD11b+CD11c+MHC-II+ cells maintained across 14 to
28 days, indicating two distinct cell types.
By 21 days, further analysis of cell subset phenotype
was possible since clear subsets of L-DC
(CD11b+CD11c+MHC-II−) and cDC-like cells
(CD11b+CD11c+MHC-II+) can be distinguished. Cells
were therefore stained with F4/80, 4-1BBL and Sirp-α
to further distinguished the two distinct dendritic-like
subsets (Fig. 2). While the cDC-like cells expressed
none of these marker, majority subsets of L-DC
expressed Sirp-α and F4/80, with a minority subset
expressing 4-1BBL (Fig. 2). Lack of CD115 and B220
expression by both DC subsets distinguished these
cells from pDC and cDC precursors [27]. The expres-
sion of F4/80 has been reported previously on some
but not all CD11c+ DC produced in spleen stromal
cultures [16, 23], and is no longer considered an ex-
clusive marker of monocytes/macrophages. The ex-
pression of 4-1BBL by L-DC is consistent with
capability of L-DC to induce CD8+ T cell proliferation
[28]. Sirp-α staining also served to distinguish the two cell
types produced in co-cultures. It is a marker expressed by
some DC and macrophage subsets but is expressed only by
L-DC in co-cultures (Fig. 2A) [29].
To determine the endocytic capacity of L-DC and
cDC-like cells produced in co-cultures, cells were col-
lected from co-cultures and incubated with ovalbumin
(OVA)-FITC. After 45 min incubation, endocytosis
was halted, and cells stained for CD11b, CD11c and
MHC-II to identify L-DC and cDC-like subsets, and
to determine capacity for uptake of OVA-FITC. L-DC
were highly endocytotic cells with 98% taking up
OVA-FITC, while only 34% of cDC-like cells were
endocytotic (Fig. 2B).
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Dendritic-like subsets differ in capacity to induce T cell
responses
In order to assess capacity of in vitro produced
dendritic-like cells for T cell activation, co-cultures were
established using Lin− BM from C57BL/6 J Act-mOVA
mice over 5G3 stroma. After 21 days, L-DC and
cDC-like cells were sorted, and these two subsets com-
pared for ability to present exogenous antigen to CD8+
T cells purified from OT-I TCR-tg mice. L-DC clearly
activated CD8+ OT-I cells, evident by upregulation of
CD69 expression on gated CD8+Vα2+Thy1.2+ T cells
after 24 h (Fig. 3A). cDC-like cells were much less
capable of activating CD8+ T cells. L-DC showed high
capacity for inducing both antigen-specific T cell activa-
tion and proliferation of CD8+ OT-I T cells after 4 days,
while cDC-like cells showed only a weak response (Fig.
3A).
Further evidence of the ability of both L-DC and
cDC-like cells to activate OT-I T cells was indicated by
the production of IL-2 and IFN-γ in the 4-day super-
natant of OT-I CD8+ T cells co-cultured with L-DC and
cDC-like cells (Fig. 4). While cDC-like cells showed only
weak activation of CD8+ T cells within 24 h (Fig. 3), they
still induced levels of IL-2 and IFN-γ comparable with T
Fig. 1 Production of cells in stromal co-cultures. Co-cultures were established by overlay of Lin− bone marrow over 5G3 stroma. (a)
Hematopoietic cells adhered to stroma were observed under phase contrast microscopy at day 21. Bar represents 100 μm. (b) Gating procedure
to detect CD11b+CD11c+ cells is shown for cells produced in co-cultures at 28-days. (c) Cell production was assessed at 14, 21 and 28 days using
antibody staining and multicolor flow cytometry. Production of the CD11b−CD11c−, CD11b+CD11c−, CD11b+CD11c+, CD11b+CD11c+MHC-II−
(L-DC) and CD11b+CD11c+MHC-II+ (cDC-like) subsets was calculated in terms of proportion of each subset amongst the total CD11b+ and/or
CD11c+ population. Graphs show mean ± S.E. for triplicate co-cultures. Cell production in terms of subset size is statistically different (p≤ 0.05) for
days 21 and 28 compared with day 14 in terms of increased dendritic cell and reduced myeloid cell production
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cells activated with L-DC, and with T cells activated by
the control APC subsets of CD8+ cDC and CD8− cDC
sorted from normal adult spleen (Fig. 4). In these experi-
ments we also showed that CD8− cDC were stronger acti-
vators of OT-I T cells than CD8+ cDC in terms of IL-2
and IFN-γ produced (Fig. 4). The production of IL-10 by
CD8− cDC activating OT-I T cells could reflect contamin-
ating regulatory DC within this sorted population (Fig. 4).
In vitro generated cDC-like cells but not L-DC reflect
DCregs
For assessment of capacity to induce CD4 T cell re-
sponses, sorted L-DC and cDC-like cells, along with
freshly isolated splenic CD11c+ cells as controls, were
cultured with CD4+ T cells purified from OT-II mice.
L-DC were unable to activate CD4+ T cells measured
through upregulation of CD69 expression within 24 h,
or to induce their proliferation after 4 days (Fig. 3B). In
contrast, cDC-like cells induced weak CD4+ T cell acti-
vation (3.6% of cells) through upregulation of CD69 ex-
pression after 24 h, while splenic CD11c+ DC showed
strong activation (10.1% of cells) (Fig. 3B). Neither L-DC
nor cDC-like cells were able to induce CD4+ T cell
proliferation while splenic CD11c+ DC were, however,
strong inducers of CD4+ T cell proliferation.
The inability to activate CD4+ T cells was also shown
through analysis of cytokine production by OT-II CD4+
cells stimulated for 4 days with sorted L-DC, cDC-like
cells, or control CD8+ cDC and CD8− cDC (Fig. 4). Nei-
ther L-DC nor cDC-like cells induced production of
IL-2, IL-4 or IFN-γ, consistent with inability to activate
or induce proliferation of OT-II CD4+ T cells (Fig. 4).
However, cDC-like cells produced high levels of IL-10 in
OT-II CD4+ T cells which is commonly associated with
regulatory or immunosuppressive DC, rather than DC
which activate T cell responses [4]. CD8+ cDC also
produced a low level of IL-10, although at 5-fold
lower level than cDC-like cells. CD8+ cDC and CD8−
cDC sorted from spleen induced production of IL-2
but not IL-4 or IFN-γ after 4 days of culture with
OT-II CD4+ T cells (Fig. 4).
The possibility that cDC-like cells are DCregs was in-
vestigated in terms of their capacity to induce differenti-
ation and activation of CD4+ OT-II T cells to Tregs.
This involves expression of FoxP3 in T cells. L-DC and
cDC-like cells were sorted from 21-day co-cultures of
Fig. 2 Phenotype of dendritic-like cells produced in co-cultures. Lin− BM from C57BL/6 J mice was overlaid on 5G3 stroma to establish co-
cultures and non-adherent cells were collected over time for staining with a range of antibodies for flow cytometric assessment of marker
expression. (A) The CD11b+CD11c+ population of dendritic-like cells produced in 21-day co-cultures was gated for further analysis of marker
expression. L-DC and cDC-like cells were distinguished through expression of MHC-II, whereby L-DC are CD11b+CD11c+MHC-II− cells and cDC-like
cells can be distinguished as CD11b+CD11c+MHC-II+ cells. Bivariate analysis of MHC-II expression with CD115, Sirp-α, F4/80, 4-1BBL, B220 and
CD8α, served to identify the phenotype of the 2 subsets. (B) Non-adherent cells collected from 21 day co-cultures were incubated with FITC-
ovalbumin (OVA) at 37 °C, or at 4 °C as control, to assess capacity of cells to endocytose antigen. At the end of incubation, cells were stained for
markers, and L-DC and cDC-like subsets gated on the basis of phenotype as CD11b+CD11c+MHC-II− and CD11b+CD11c+MHC-II+ cells,
respectively. These were then assessed flow cytometrically for endocytosis in terms of % cells taking up FITC-ovalbumin (OVA) (red histogram)
compared with controls (blue histogram)
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Lin− bone marrow over 5G3 and compared for ability to
induce FoxP3 expression in sorted CD4+ OT-II T cells
along with control CD11c+ spleen cells. This involved
flow cytometric assessment of FoxP3 expression through
intracellular staining of gated CD4+ T cells. The re-
sponse due to cDC-like cells showed 39% of CD4+ T
cells expressing FoxP3 at an APC:T cell ratio of 1:10,
compared with almost none (0.8%) for L-DC, with a par-
tial response (14%) for splenic CD11c+ DC (Fig. 3B).
This result supported the finding of IL-10 production by
CD4+ OT-II T cells following incubation with cDC-like
cells, but not with L-DC (Fig. 4). These two distinct re-
sults are consistent with the hypothesis that cDC-like
cells are DCregs.
Differential gene expression by L-DC and cDC-like cells
Expression of 84 genes identified as markers of murine
DC and APC was assessed for the L-DC and cDC-like
subsets sorted out of 28-day co-cultures of Lin− bone
marrow cells over 5G3 stroma. RNA was prepared for
realtime PCR involving the RT2 Profiler PCR array pro-
duced by SABiosciences. Results were averaged from
two separate sorting experiments. Fifty out of 84 genes
were differentially expressed by ≥ 2-fold between the two
subsets (Table 1). The differential gene expression pro-
files are consistent with two distinct dendritic-like cell
types.
The majority of genes upregulated in L-DC encode
markers of mature, immunostimulatory DC. These in-
clude Il12a (interleukin 12α), Il12b (interleukin 12β),
Ifng (interferon γ), Il6 (interleukin 6) and Il2 (interleukin
2), as well as genes encoding cell surface markers of DC
including Cd80, Cd4, CD8a, CD40 and Adamdec1 [30,
31]. Cells also express Relb which is expressed by acti-
vated DC [32], as well as Vcl (vinculin) important for
antigen uptake [33], and Cd1d2 encodes an MHC-like
antigen presenting molecule for activation of Natural
Killer T cells [34]. These cells also show upregulation of
Fig. 3 Ability of DC produced in co-cultures to induce T cell responses. Co-cultures were established by overlay of Lin− BM from Act-mOVA mice
above 5G3 stroma and non-adherent cells collected after 21 days. Cells were stained for CD11b, CD11c and MHC-II expression and subsets of
L-DC and cDC-like cells sorted and then incubated with CD8+ T cells purified from OT-I TCR-tg mice specific for OVA257–264/H-2K
b or OT-II TCR-tg
mice specific for OVA323–339/H-2IA
b at APC:T cell ratios of 1:10, 1:100 and 1:1000. Controls included T cells only with no APC. Control APC included
CD11c+ DC from spleen. (a) Cells for analysis of OT-I responses were collected from cultures and gated as live (PI−) Thy1.2+Vα2+CD8+ T cells. T
cell activation was measured at 24 h in terms of % cells expressing CD69. T cell proliferation was measured after 4 days in terms of a reduction in
CFSE staining. Data represent mean ± S.E. of three replicate co-cultures. L-DC gave statistically greater T cell activation across all three APC:T cell
ratios, while statistically greater T cell proliferation was noted only at an APC:T cell ratio of 10:1 (p≤ 0.05). (b) Cells for analysis of OT-II responses
were collected from cultures and T cells gated as live (PI−) Thy1.2+Vα2+CD4+ cells. T cell activation was measured at 24 h as % cells expressing
CD69. T cell proliferation was measured at 4 days in terms of reduction in CFSE staining. Production of regulatory T cells was assessed through
intracellular Foxp3 expression in CD4+ T cells analysed after 4 days by flow cytometry
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genes for the proinflammatory factor Ccl20 (MIP-3A),
and chronic inflammatory factors Ccl5 and Ccl11.
Genes upregulated by cDC-like cells reflect a myeloid
dendritic cell type with potential immunosuppressive
capacity in line with classification of cells as DCregs.
The most highly upregulated genes included Fcer1a
which encodes an Fc receptor for IgE binding which
could trigger DC to activate T cells in response to aller-
gen exposure. The cells also express Tlr2 encoding
toll-like receptor 2, which makes them sensitive to
pathogen activation. However, several other upregulated
genes suggest capacity of cDC-like cells to be involved
in suppressive responses. Expression of Inhba encoding
activin-βΑ a member of the TGF-β family, is consistent
with capacity to induce formation of T regs [35]. Expres-
sion of Itgb2 which encodes β2 integrin can lead to sup-
pression of Toll-like receptor stimulation [36]. Several
other genes encoding chemokines associated with in-
flammatory responses associated with autoimmunity
were found to be upregulated. These included Ccl8,
Fig. 4 Cytokine release upon DC activation of antigen-specific T cells. The release of IL-2, IL-4, IL-10 and IFN-γ by OT-I and OT-II T cells following
stimulation with different APC subsets was investigated. L-DC and cDC-like subsets were sorted from 21-day co-cultures established with Lin− BM
from Act-mOVA mice above 5G3 stroma. Control CD8+ cDC and CD8− cDC subsets were sorted from Act-mOVA spleen. These four APC subsets,
and a NIL control, were incubated with column purified CD8+ OT-I T cells and CD4+ OT-II T cells from spleen for 4 days. The supernatant of
co-cultures was collected, tested for the presence of cytokines using an Elisa array kit (Qiagen), and production calculated as A450 of sample
relative to A450 of a standard provided with the kit
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Ccl7, Ccl2, Ccl12 and Tnf. Myeloid cell characteristics of
cDC-like cells are indicated by expression of Cebpa, a
transcription factor for DC development from progeni-
tors [37], Cd33 which encodes a marker of myeloid and
also myeloid suppressor cells [38], Csfr1 encoding
MCSFR a common marker of myeloid lineage mono-
cytes/macrophages, Cd36 which encodes a phagocytic
receptor [39], Mif which encodes a suppressive factor in-
volved in phagocytosis, recognition and engulfment of
antigen [40], and Ccr5 which encodes a chemokine re-
ceptor present on DC entering inflammatory sites [41].
M-CSF directs the development of DCregs in stromal co-
cultures
Previously it was shown that the production of L-DC in
co-cultures established above 5G3 splenic stroma could
be completely inhibited if bone marrow progenitors
were plated above a Transwell membrane to prevent
cell-cell contact with the stromal cell monolayer [24].
These co-cultures generated instead an enriched popula-
tion of cells highly enriched for cDC-like cells. Previous
studies from this lab also identified macrophage colony
stimulating factor (MCSF) as an important factor for the
generation of cDC-like cells [16], and this is produced at
high levels by splenic stromal lines [42]. In contrast,
L-DC production was entirely dependent on stromal cell
interaction [16]. Data in Table 1 has confirmed nearly
3-fold higher expression of Csfr1 in cDC-like cells com-
pared with L-DC after 28 days of co-culture, despite the
fact that cells have lost cell surface receptor expression
for CD115 (CSFR1/MCSFR) (Fig. 2).
Co-cultures established with Lin− bone marrow pro-
genitors seeded above a Transwell membrane preventing
contact with stroma, were highly productive of cDC-like
cells with no L-DC production (Fig. 5). The production
of cDC-like cells doubled across 7 to 21 days and main-
tained this level of production over 35 days. MCSF de-
pendency for cell production under non-contact growth
conditions was confirmed through addition of the spe-
cific MCSFR inhibitor GW2580. This was replenished
every 3 days at medium change. After 14 days of culture
in the presence of inhibitor, production of cDC-like
CD11c+CD11b+MHCII+ cells had ceased (Fig. 5A and
B). Following 21 days of treatment, cultures were then
returned to normal medium, and the production of cells
resumed, reaching equivalence with control cultures by
35 days (Fig. 5B). Post recovery cells at 28 days showed
the same phenotypic characteristics as cells produced in
control cultures (Fig. 5A). This result confirms that in-
hibition of MCSFR served only to prevent the produc-
tion of cells and did not destroy the progenitor/
precursor population over 21 days of treatment.
Discussion
This study confirms the work of others by demonstrat-
ing the ability to produce DCregs from bone marrow
progenitors cultured above spleen stroma [9, 11–13]. It
goes further, however, in that it differentiates the pro-
duction of DCregs from the novel L-DC subset reported
previously by this lab. L-DC reflect a novel dendritic-like
cell type produced continuously in spleen stromal
co-cultures overlaid with bone marrow progenitors [14,
15]. An in vivo equivalent L-DC subset was recently de-
scribed in both murine [43] and human spleen [44],
which gives physiological relevance to the hematopoietic
process giving rise to L-DC in vitro. L-DC are quite dis-
tinct, both phenotypically and functionally, from all
known myeloid and dendritic cell types in spleen, in-
cluding DCregs [43, 45]. A series of studies have also de-
termined that L-DC develop independently of MCSF,
FLT3L, GMCSF, and also without BATF3 expression
which drives cDC and pDC development [45], and also
Table 1 Genes upregulated in L-DC or cDC-like cells
Gene L-DC/cDC-like Gene cDC-like/L-DC
Ccl20 7.30 Fcer1a 14.44
Il12a 5.53 Ccl8 7.96
Cd8a 5.38 Ccl7 5.78
Cxcl12 4.99 Ccr3 5.43
Ccl19 4.88 Fcgrt 5.25
Ifng 4.31 Fcer1g 5.21
Cxcl10 4.16 Inhba 4.83
Vcl 3.86 Cd2 3.92
Cd1d2 3.75 Cd36 3.79
Relb 3.50 Cxcl2 3.64
Il8ra 3.48 Tlr2 3.51
Adamdec1 3.41 Ccl2 3.42
Il2 3.31 Mif 3.42
Ifit3 3.29 Ccl12 3.39
Erbb2 3.11 Ccr5 3.37
Icam2 2.99 Csf1r 2.72
Ccl5 2.84 Ccr1 2.62
Ccr2 2.58 Cd33 2.55
Icam1 2.39 Itgb2 2.22
Ccl11 2.34 Il16 2.19
Fcer2a 2.33 Cebpa 2.18
Cd80 2.31 Tnf 2.16
Cd4 2.25 Cdc42 2.00
Cd40 2.23
Trap1 2.14
Il12b 2.11
Il6 2.11
Realtime PCR was performed using an RT2 Profiler PCR Array (SABiosciences)
to measure the relative expression of genes common to murine dendritic and
antigen presenting cells by sorted populations of L-DC and cDC-like cells
isolated from 28-day co-cultures. Genes upregulated ≥ 2-fold in L-DC or cDC-
like cells are listed
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c-MYB, a transcription factor important in the develop-
ment of bone marrow-derived myeloid cells [16, 46]. All
work to date points to L-DC arising from hematopoietic
progenitors endogenous to spleen which may have been
laid down in spleen during embryogenesis.
This study investigates the cDC-like population of cells
produced transiently in spleen stromal co-cultures
seeded with bone marrow and demonstrates the unique
importance of MCSF in their development. While other
soluble factors produced by 5G3 may direct cDC-like
cell development, these are not deterministic. In our
hands, production of cDC-like cells reflecting DCregs
depends on the prevention of L-DC production in
co-cultures established from Lin− bone marrow by using
a Transwell membrane. The latter method introduces a
simple procedure with application in production of au-
tologous DCregs for therapeutic use.
An important role for MCSF has been confirmed in
the production of cDC-like cells in co-cultures. While
neither the L-DC or cDC-like subsets produced in Lin−
bone marrow co-cultures over 5G3 stroma expressed
CD115 (MCSFR) after 28 days of co-culture (Fig. 2), this
Fig. 5 MCSF-dependency of DCreg development. Co-cultures were established by overlay of Lin− BM from C57BL/6J mice above a Transwell
membrane to prevent contact of between hematopoietic progenitors and 5G3 stroma. Three replicates cultures were treated with the M-CSFR
inhibitor GW2580 (10 mM), or left untreated (controls), with inhibitor replenished every 3 days at medium change. Treatment continued for
21 days, followed by a period of 14 days in the absence of inhibitor to assess recovery. Cell production was analysed flow cytometrically every
7 days through antibody staining to detect CD11b, CD11c and MHC-II expression and to delineate CD11c+CD11b+MHC-II+ cDC-like cells. (a)
Gating procedure for identification of cDC-like cells produced in 14-day Transwell co-cultures in the presence of inhibitor and in 28-day
co-cultures after inhibitor has been washed out. Controls contained no inhibitor. (b) Production of DCregs in Transwell co-cultures expressed in
terms of number of cDC-like cells produced over time relative to cell number produced in 7-day control cultures. Data represent mean ± SE of
three replicate co-cultures. Addition of GW2580 significantly inhibited cell production relative to control at each 7-day interval out to
28 days (p≤ 0.05)
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result does not preclude a role for MCSF in the early de-
velopment of cells from myeloid progenitors/precursors
or monocytes in co-cultures. Since MCSF is important
in cell development it is likely that DCregs develop from
a CD115+ precursor present in bone marrow which dif-
ferentiates in response to MCSF produced by stroma.
This is consistent with former work showing that pro-
genitors of the cDC-like population were present within
each of the defined subsets of Lin−Sca1−ck-
ithiFlt3+CD115+CX3CR1− myeloid progenitors [47, 48],
the Lin−Sca1−ckithiFlt3+CD115+CX3CR1+ myeloid/den-
dritic progenitor subset [49], and the Lin−Sca1−cki-
tloFlt3+CD115+ common dendritic progenitor subset
[50]. There is still ambiguity about the delineation of
these three progenitor subsets, and evidence that they
reflect overlapping subsets [49], a finding consistent with
CD115 expression by precursors of DCregs. Further-
more, dependency on MCSF for development also serves
to distinguish cDC-like cells from CD8− cDC and con-
firms that they were not immediate precursors of cDC
or pDC [27, 51].
In light of evidence for a role of M-CSF in the devel-
opment of cDC-like cells reflective of DCregs, the ques-
tion of whether co-cultures over spleen stroma produce
myeloid lineage cells or macrophages needs to be ad-
dressed. Over many studies we have shown that
co-cultures established with Lin− bone marrow produce
a low yield of CD11b+CD11c−MHC-II− cells which we
have classified as ‘myeloid’. These cells could be either
myeloid progenitors/precursors or monocytes/macro-
phages. Most recently, the studies of Periasamy et al.
[16] identify a small population of these cells after
14 days of co-culture which are almost gone by 21 days.
Petvises & O’Neill [24] also shows evidence of a small
population produced in co-cultures of Lin− bone mar-
row over 5G3 stroma. They are only detectable in
co-cultures using Lin− bone marrow as a source of pro-
genitors and are not produced in co-cultures established
with purified HSPC [16]. Hence the myeloid subset may
arise from myeloid progenitors/precursors present in
Lin− bone marrow. Since this population is only
enriched (95%) through magnetic bead depletion, it is
possible that it also contains some more mature myeloid
cells as contaminants. Because of the small size of this
population, myeloid cell production has not been inves-
tigated further. Since these cells are transiently produced
over just several weeks, they have not been of interest in
light of the evidence that L-DC are produced continu-
ously, and cDC-like cells are produced in higher
numbers.
Previous evidence showed that the addition of a Trans-
well to co-cultures of Lin− bone marrow co-cultured
with 5G3 stroma inhibited L-DC production and gave a
marked increase in cDC-like cell production [24]. These
results suggested that L-DC production was dependent
on stromal cell contact, while cDC-like production was
not. Further studies performed in the absence of a
Transwell, showed that addition of the MCSFR inhibitor
GW2580 affected production of dendritic-like cells
which was manifest as a loss of cDC-like cells
(CD11b+CD11c+MHC-II+) with an increase in L-DC
(CD11b+CD11c+MHC-II−) production [16]. This sug-
gested that the production of the two cell types was dis-
tinct and in dynamic equilibrium, with the L-DC subset
dependent on stromal contact and the cDC-like subset
dependent on M-CSF for development. These Lin− bone
marrow co-cultures showed very low production of
CD11b+CD11c− myeloid cells, which was not inhibited
by GW2580 [16]. Figure 5 now shows Lin− bone marrow
co-cultures established in the presence of a Transwell,
where many more cDC-like cells than L-DC are pro-
duced. This is distinct from results shown in Fig. 2,
where similar co-cultures established in the absence of a
Transwell, produce more L-DC than cDC-like cells. The
data in Fig. 5 then shows clearly that production of
cDC-like cells above the Transwell can be very effect-
ively inhibited by GW2580, suggesting dependency on
M-CSF for production.
While little is known about the development and
lineage origin of DCregs, it is clear that the population is
heterogeneous both in the mouse and human models.
DCregs are known to retain the ability to present anti-
gen for activation of T cells, evident through their ability
to activate CD8+ T cells [6]. However, DCregs downreg-
ulate their capacity to activate CD4+ T cells through
downregulation of IL-12 production and reduced ex-
pression of markers like MHC-II, CD80, CD86 and
CD40. At the same time, they also increase their im-
munosuppressive capacity through expression of inhibi-
tory molecules like CD95L, IDO and PDL1, and
production of inhibitory cytokines like TGF-β and IL-10
[4, 6]. DCregs produced here show functional evidence
of their immunosuppressive capacity through secretion
of IL-10 upon co-culture with antigen-specific CD4+ T
cells. In comparison with L-DC, they also show upregu-
lation of genes reflective of myeloid dendritic cells which
have inflammatory and immunosuppressive characteris-
tics rather than activating capacity.
Currently few markers are available which are delin-
eating for DCreg subsets, and discovery has been im-
peded by the inability to isolate large numbers of these
cells for characterization. The development and role of
DCregs is not well understood, and more than one path-
way for development is apparent. The availability of re-
producible tissue culture systems for production of cells
should allow transcriptome analysis and the delineation
of transcription factors and gene pathways driving cell
development. DCregs represent an important
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therapeutic tool for the induction of Tregs which can
control autoimmunity, inflammation, and unwanted T
cells, for example during tissue graft rejection.
Conclusion
A co-culture system of hematopoietic progenitors over
splenic stroma has been shown to produce two distinct
DC subsets. Since similar culture systems have been
shown to yield DCregs, the two APC subsets were com-
pared in terms of phenotype and function in T cell acti-
vation. Here the cDC-like population produced in
co-cultures of lineage-depleted (Lin−) bone marrow over
the 5G3 murine spleen stromal line has been shown to
resemble DCregs. Conditions which support specific
M-CSF-dependent production of these cells in the ab-
sence of L-DC have been defined offering a means for
production of enriched populations of these elusive cells,
perhaps for specific therapeutic use.
Methods
Animals
Specific pathogen-free female C57BL/6.Tg
(TcraTcrb)1100Mjb (OT-I), C57BL/6.SJL/J.OT-II.CD45.1
(OT-II), C57BL/6.Tg (CAG-OVA) 916Jen:WehiAnu
(Act-mOVA) and C57BL/6J mice were bred at the John
Curtin School of Medical Research (JCSMR) (Canberra,
Australia). Protocols covering housing, handling and ex-
perimentation of animals were approved by the Animal
Experimentation Ethics Committee (Australian National
University, Canberra, Australia). Animals were sacrificed
by cervical dislocation.
Antibodies
Fluorochrome-conjugated antibodies specific for CD4
(GK1.5), Thy1.2 (30-H12), CD69 (H12F3), B220 (RA3-6B2),
MHC-II (AF6–120.1), F4/80 (C1: A3–1), CD8α (53–6.7),
Sirp-α (P84), 4-1BBL (TKS-1), streptavidin-PE-Cy7,
streptavidin-PE and streptavidin-FITC were obtained from
Biolegend. Fluorochrome-conjugated antibodies specific for
CD11c (N418), CD11b (M1/70), CD115 (AFS98) and
streptavidin-APC-Cy7 were obtained from eBiosciences
(San Diego, CA, USA) or Biolegend (San Gabriel, CA,
USA). Isotype control antibodies including Rat IgG2a-FITC
(R35–95), Rat IgG2b-PE (RTK4530), Rat IgG2b-PE-Cy7
(eB149/10H5), Mouse IgG2a-biotin (eBM2a) and Hamster
IgG-APC (eBio299Arm) were obtained from eBioscience.
Preparation of bone marrow cells
This procedure has been described in detail previously
[16]. Briefly, medium (DMEM: 5 ml) was used to flush
bone marrow from femurs. Cells were centrifuged and
resuspended in red blood cell lysis buffer (140 mM
NH4CL, 17 mM Tris Base [pH 7.5]) for removal of red
cells. Lin− bone marrow was prepared using a lineage
depletion kit (Miltenyi Biotech, Gladbach, Germany)
containing biotinylated antibodies specific for all
hematopoietic lineages (7–4, CD5, CD11b, CD45R,
Ly6G/C and Ter119) to which was added antibody spe-
cific for CD11c (HL3: Becton Dickinson Pharmingen,
San Diego, CA, USA) to deplete DC. Anti-biotin
microbeads in MS or LS columns (Miltenyi Biotech)
were used to purify Lin− bone marrow cells.
Establishment of 5G3 co-cultures
Cells were cultured as described previously [16] in Dul-
becco’s modified Eagles Medium (DMEM) supple-
mented with 4 g/L D-glucose, 6 mg/L folic acid, 36 mg/
L L-asparagine, 116 mg/L L-arginine, to which was
added 10% fetal calf serum, 10 mM HEPES, 2 mM L-glu-
tamine, 100 U/L penicillin, 100μg/L streptomycin, and
5 × 10−5M 2-mercaptoethanol (sDMEM). The stromal
cell line 5G3 [20–22] was passaged every 3–4 days by
scraping and transfer of non-adherent cells to a new
flask. Cells were maintained in 5% CO2 in 95% humidity
at 37 °C. For establishment of co-cultures, Lin− bone
marrow cells (104–5 cells/ml) were overlaid on to
near-confluent 5G3 stroma in replicate 25cm2 flasks as
described previously [22–24]. Medium change was per-
formed every 3–4 days by replacement of 2.5 ml
medium with 2.5 ml sDMEM. This yielded a 5- to
10-fold increase in cell number. Non-adherent cells were
collected at days 14, 21 and 28 for analysis of subsets
produced. Transwell experiments were achieved by over-
lay of 104–5 cells/ml Lin− bone marrow cells on to
Transwell membranes above 5G3 stroma. For inhibition
studies, 104–5 cells/ml Lin− bone marrow cells from
C57BL/6 J mice were overlaid on to 5G3 stroma in the
presence and absence of the MCSFR inhibitor GW2580
used at 10 nM (BioVision, CA, USA).
Analysis of cells produced in co-cultures
Non-adherent cells collected from co-cultures at each
time point were stained with antibodies specific for mye-
loid and dendritic-like cells. As described previously [16,
24, 25], 105–6 cells were incubated with CD16/32 anti-
body (Clone 93; eBioscience) for 15 min to block surface
Fc receptors. Cells were then washed with DMEM/
1%FCS/0.1%NaN3 (FACS buffer) and stained with pri-
mary antibodies specific for CD8α, B220, CD115, F4/80,
4-1BBL, CD11c, CD11b, MHC-II and Sirp-α for 20 min
on ice. Secondary fluorochrome conjugates were added
after a washing step and incubated for a further 20 min
on ice. Cells were then washed twice and resuspended in
FACS buffer for flow cytometric analysis. Cells were
stained with propidium iodide (PI) (1 μg/ml) for live cell
discrimination in order to gate PI− live cells. FSC versus
SSC plots were used to gate large cells for marker ana-
lysis. Cell acquisition involved use of a LSR II flow
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cytometer (Becton Dickinson), and between 5 × 104 and
1 × 106 events were collected for each sample. Gates
were set to delineate cell subsets using isotype control
antibodies and ‘fluorescence minus one’ (FMO) controls.
Numbers on gates reflect % positive cells. Cell subset
analysis was performed using BD FACSDiva Software
(Becton Dickinson) and FlowJo Software (Tristar; Phoe-
nix, Arizona, USA).
Endocytosis
Capacity of cells to take up antigen was assessed by in
vitro measurement of endocytosis as described previ-
ously [23]. Cells were washed twice with DMEM and
placed on ice for 10 min. FITC-conjugated ovalbumin
(OVA-FITC) (Molecular Probes, Eugene, OR, USA)
(2 μg/ml) was added and cells incubated at 37 °C for
45 min, or at 4 °C as a control. The addition of 100 μl
chilled PBS/0.1%NaN3 was used to halt the reaction.
Cells were washed thrice by centrifugation at 300 g and
4 °C for 5 min, supernatant discarded completely, and
cells resuspended in 70 μl of FACS buffer for flow cyto-
metric analysis.
Purification of T cell subsets
This procedure was described previously [24]. Briefly,
spleen cells were resuspended in medium containing
monoclonal antibodies specific for APC including macro-
phages, B cells and DC. The antibody cocktail contained
anti-CD11b (clone: M1/70), anti-B220 (clone: RA3-6B3)
and anti-IAb/k (clone: TIB120) per 107 cells. For depletion
of CD4+ or CD8+ T cells, either anti-CD4 (GK1.5) or
anti-CD8 (53–6.7) was included in the cocktail. Cells were
incubated with antibodies on ice for 25 min followed by
washing twice with buffer. Supernatant was discarded
completely, and cells then incubated with sheep anti-rat Ig
Dynabeads® (Invitrogen Dynal: AS, Oslo, Norway) (50 μl
beads/107cells) at 4 °C for 25 min with rotation. Sheep
anti-rat Ig Dynabeads® were washed twice with buffer
prior to use. Following incubation, cells were placed in a
Dynal® magnetic particle separator for 2 min. Supernatant
containing unbound T cells was transferred into a new
tube. Enriched T cell subsets were washed, and cell num-
ber determined before use.
T cell activation and proliferation
The procedures used here were adapted from previously
published protocols [24]. Splenic CD8+ T cells purified
from OT-I T cell receptor (Vα2)-transgenic (TCR-tg)
mice specific for ovalbumin (OVA257–264/H-2K
b) were
employed to determine the antigen presentation capacity
of DC. APC were isolated as L-DC sorted as
CD11b+CD11c+MHC-II− and cDC-like cells sorted as
CD11b+CD11c+MHC-II+ from 21-day co-cultures of
Lin− BM from Act-mOVA mice cultured above 5G3
stroma. Splenic CD11c+ cells from Act-mOVA mice
were prepared as control DC. All DC subsets were
plated in 96-well plates in sDMEM together with puri-
fied splenic OT-I CD8+ T. APC and T cell were plated at
ratios of 1:10, 1:100, and 1:1000, in a total volume of
200 μl. Cells were incubated at 37 °C, 5% CO2 in air and
95% humidity for 24 h, and then CD8+T cells assessed
for activation through expression of CD69. For assess-
ment of CD8+ T cell proliferation, similar experiments
were conducted using CFSE-labeled CD8+ T cells. Cells
were cultured for 4 days and then stained with antibody
to CD8, Vα2 and Thy1.2, and proliferation determined
in terms of CFSE dilution by flow cytometry. Super-
natant was collected and frozen at − 20 °C for determin-
ation of cytokine released.
The ability of APC subsets to present antigen to CD4+
T cells was demonstrated through ability of
antigen-pulsed cells to induce proliferation of purified
CD4+ T cells isolated from OT-II TCR (Vα2)-tg mice
specific for ovalbumin (OVA323–339/H-2IA
b). Procedures
for isolation of DC subsets for measurement of T cell ac-
tivation and proliferation were similar to those described
above for OT-I CD8+ T cells.
Induction of regulatory T cells
Assessment of intracellular Foxp3 expression was used
to identify regulatory T cells. Activated CD4+ T cells
were prepared as described above. These were stained
with antibodies specific to CD4, Vγ2 and Thy1.2 prior to
resuspension in 200 μl of Foxp3 Fix/Perm solution (Bio-
legend) and incubation in the dark for 20 min. Cells
were washed once with FACS buffer, followed by wash-
ing with Foxp3 Fix/Perm buffer. Supernatant was dis-
carded completely, and cells resuspended in 200 μl
Foxp3 Perm buffer (Biolegend). Cells were incubated in
the dark for a further 15 min and then centrifuged to re-
move supernatant. The pellet was resuspended in 20 μl
anti-Foxp3-PE conjugate (Biolegend) with incubation in
the dark for 30 min. Cells were washed twice with FACS
buffer and Foxp3 expression determined by flow cyto-
metric analysis.
Quantitative polymerase chain reaction
The procedure used follows a similar protocol used pre-
viously [24]. L-DC and cDC-like cells were sorted from
28-day co-cultures of Lin− bone marrow over 5G3. RNA
was extracted using the RNeasy mini kit (Qiagen, Clifton
Hill, Australia) and was converted to cDNA using the
RT2 First Strand Synthesis Kit (Qiagen). To perform
real-time quantitative reverse transcriptase polymerase
chain reactions (qRT-PCR), cDNA, RT2 SYBR Green
Mastermix, and RNAse-free water were added directly
to PCR arrays already loaded with primers for 84 genes
related to mouse dendritic and antigen presenting cells
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(PAMM-406A PCR array: SABiosciences, Frederick,
MD, USA). The plate was loaded on to a Roche LightCy-
cler 480 (Roche, Castle Hill, Australia). Cycling condi-
tions were: 1 cycle of 10 min at 95 °C, followed by
45 cycles of 15 s at 95 °C, and 1 min at 60 °C. Data ana-
lysis was performed using Roche LightCycler 480 soft-
ware version 1.2.9.11 to calculate the cycle number at
which the maximal increase in fluorescence emission oc-
curs in the log-linear phase (threshold cycle Ct). Ct
values were calculated for genes of interest (GOI) and
housekeeping genes (HKG): ΔCt = Ct(GOI) – Ct(HKG).
The average ΔCt was taken from duplicate experiments.
The fold change difference between two samples was
calculated as 2-ΔCt (sample 1)/2-ΔCt (sample 2), giving
the relative difference in mRNA quantity between 2
samples for any gene of interest. Technical replicates
were averaged for each sample and production of an
amplified product validated through gel electrophoresis.
Measurement of cytokines
The production of IL-2, IL-4, IL-10 and IFN-γ released
from activated T cells after incubation with DC subsets
for 4 days was measured. A 50 μl aliquot of T cell super-
natant was collected and added to the wells of an ELI-
SArray plate containing pre-coated capture antibodies
(Qiagen; Victoria, Australia). The plate was incubated on
ice for 2 h, followed by washing thrice with 200 μl PBS
and centrifugation at 300 g and 4 °C for 5 min. Super-
natant was discarded and 100 μl of detection antibody
added to each well. The plate was then incubated on ice
for a further hour, followed by washing thrice. Super-
natant was discarded and 100 μl of avidin-horseradish
peroxidase (Avidin-HRP) added to each well, followed
by incubation on ice for 15 min, and washing thrice.
The supernatant was discarded and 100 μl of developing
solution added. A450 was read using FLUOstar Optima
microplate reader (BMG Labtech; Durham, NC, USA).
Cytokine production was calculated as A450 of sample
relative to A450 of a standard provided with the kit and
expressed as % of maximum.
Statistical analysis
Statistical analysis involved the pairwise comparison
of replicated cultures which were established at the
same time, and in some cases assayed at several time
points. The statistical procedure used involved a Bon-
ferroni Correction to the significance level of the Stu-
dent’s t-test used to assess significance (p ≤ 0.05),
reflecting the fact that multiple comparisons were
made together. Data are presented as mean ± standard
error (SE) for sample size n.
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